GONAL-f

Land: Europese Unie

Taal: Engels

Bron: EMA (European Medicines Agency)

Koop het nu

Bijsluiter Bijsluiter (PIL)
09-10-2023
Productkenmerken Productkenmerken (SPC)
09-10-2023

Werkstoffen:

follitropin alfa

Beschikbaar vanaf:

Merck Europe B.V.

ATC-code:

G03GA05

INN (Algemene Internationale Benaming):

follitropin alfa

Therapeutische categorie:

Sex hormones and modulators of the genital system,

Therapeutisch gebied:

Anovulation; Reproductive Techniques, Assisted; Infertility, Female; Hypogonadism

therapeutische indicaties:

Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT).GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level

Product samenvatting:

Revision: 26

Autorisatie-status:

Authorised

Autorisatie datum:

1995-10-20

Bijsluiter

                                124
B. PACKAGE LEAFLET
125
PACKAGE LEAFLET: INFORMATION FOR THE USER
GONAL-F
75 IU POWDER AND SOLVENT
FOR SOLUTION FOR INJECTION
follitropin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What GONAL-f is and what it is used for
2.
What you need to know before you use GONAL-f
3.
How to use GONAL-f
4.
Possible side effects
5.
How to store GONAL-f
6.
Contents of the pack and other information
How to prepare and use the GONAL-f powder and solvent
1.
WHAT GONAL-F IS AND WHAT IT IS USED FOR
WHAT GONAL-F IS
GONAL-f contains a medicine called “follitropin alfa”. Follitropin
alfa is a type of “follicle
stimulating hormone” (FSH) which belongs to the family of hormones
called “gonadotropins”.
Gonadotropins are involved in reproduction and fertility.
WHAT GONAL-F IS USED FOR
IN ADULT WOMEN,
GONAL-f is used:
•
to help release an egg from the ovary (ovulation) in women that cannot
ovulate and that did not
respond to treatment with a medicine called “clomiphene citrate”.
•
together with another medicine called “lutropin alfa”
(“luteinising hormone” or LH) to help
release egg from the ovary (ovulation) in women whose body is
producing very little
gonadotropins (FSH and LH).
•
to help develop several follicles (each containing an egg) in women
undergoing assisted
reproductive technology procedures (procedures that may help you to
become pregnant) such as
“
_in vitro_
fertilisation”, “gamete intra-fallopian transfer” or “zygote
intra-fallopian transfer”.
IN ADULT
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
GONAL-f 75 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 5.5 micrograms of follitropin alfa* equivalent to
75 IU. Each mL of the
reconstituted solution contains 75 IU.
* recombinant human follicle stimulating hormone (r-hFSH) produced in
Chinese Hamster Ovary
(CHO) cells by recombinant DNA technology
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
Appearance of the powder: white lyophilised pellet.
Appearance of the solvent: clear colourless solution.
The pH of the reconstituted solution is 6.5 to 7.5.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
In adult women
•
Anovulation (including polycystic ovarian syndrome) in women who have
been unresponsive to
treatment with clomiphene citrate.
•
Stimulation of multifollicular development in women undergoing
superovulation for assisted
reproductive technologies (ART) such as
_in vitro_
fertilisation (IVF), gamete intra-fallopian
transfer and zygote intra-fallopian transfer.
•
GONAL-f in association with a luteinising hormone (LH) preparation is
indicated for the
stimulation of follicular development in women with severe LH and FSH
deficiency.
In adult men
_ _
•
GONAL-f is indicated for the stimulation of spermatogenesis in men who
have congenital or
acquired hypogonadotrophic hypogonadism with concomitant human
chorionic gonadotropin
(hCG) therapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with GONAL-f should be initiated under the supervision of a
physician experienced in the
treatment of fertility disorders.
Posology
The dose recommendations given for GONAL-f are those in use for
urinary FSH. Clinical assessment
of GONAL-f indicates that its daily doses, regimens of administration,
and treatment monitoring
procedures should not be different from those currently used for
urinary FSH-containing medicinal
products. It is advised to a
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Bulgaars 09-10-2023
Productkenmerken Productkenmerken Bulgaars 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Bulgaars 28-09-2010
Bijsluiter Bijsluiter Spaans 09-10-2023
Productkenmerken Productkenmerken Spaans 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Spaans 28-09-2010
Bijsluiter Bijsluiter Tsjechisch 09-10-2023
Productkenmerken Productkenmerken Tsjechisch 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Tsjechisch 28-09-2010
Bijsluiter Bijsluiter Deens 09-10-2023
Productkenmerken Productkenmerken Deens 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Deens 28-09-2010
Bijsluiter Bijsluiter Duits 09-10-2023
Productkenmerken Productkenmerken Duits 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Duits 28-09-2010
Bijsluiter Bijsluiter Estlands 09-10-2023
Productkenmerken Productkenmerken Estlands 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Estlands 28-09-2010
Bijsluiter Bijsluiter Grieks 09-10-2023
Productkenmerken Productkenmerken Grieks 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Grieks 28-09-2010
Bijsluiter Bijsluiter Frans 09-10-2023
Productkenmerken Productkenmerken Frans 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Frans 28-09-2010
Bijsluiter Bijsluiter Italiaans 09-10-2023
Productkenmerken Productkenmerken Italiaans 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Italiaans 28-09-2010
Bijsluiter Bijsluiter Letlands 09-10-2023
Productkenmerken Productkenmerken Letlands 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Letlands 28-09-2010
Bijsluiter Bijsluiter Litouws 09-10-2023
Productkenmerken Productkenmerken Litouws 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Litouws 28-09-2010
Bijsluiter Bijsluiter Hongaars 09-10-2023
Productkenmerken Productkenmerken Hongaars 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Hongaars 28-09-2010
Bijsluiter Bijsluiter Maltees 09-10-2023
Productkenmerken Productkenmerken Maltees 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Maltees 28-09-2010
Bijsluiter Bijsluiter Nederlands 09-10-2023
Productkenmerken Productkenmerken Nederlands 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Nederlands 28-09-2010
Bijsluiter Bijsluiter Pools 09-10-2023
Productkenmerken Productkenmerken Pools 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Pools 28-09-2010
Bijsluiter Bijsluiter Portugees 09-10-2023
Productkenmerken Productkenmerken Portugees 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Portugees 28-09-2010
Bijsluiter Bijsluiter Roemeens 09-10-2023
Productkenmerken Productkenmerken Roemeens 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Roemeens 28-09-2010
Bijsluiter Bijsluiter Slowaaks 09-10-2023
Productkenmerken Productkenmerken Slowaaks 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Slowaaks 28-09-2010
Bijsluiter Bijsluiter Sloveens 09-10-2023
Productkenmerken Productkenmerken Sloveens 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Sloveens 28-09-2010
Bijsluiter Bijsluiter Fins 09-10-2023
Productkenmerken Productkenmerken Fins 09-10-2023
Bijsluiter Bijsluiter Zweeds 09-10-2023
Productkenmerken Productkenmerken Zweeds 09-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Zweeds 28-09-2010
Bijsluiter Bijsluiter Noors 09-10-2023
Productkenmerken Productkenmerken Noors 09-10-2023
Bijsluiter Bijsluiter IJslands 09-10-2023
Productkenmerken Productkenmerken IJslands 09-10-2023
Bijsluiter Bijsluiter Kroatisch 09-10-2023
Productkenmerken Productkenmerken Kroatisch 09-10-2023

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten